The Life Extension Advocacy Foundation volunteers hosted their first conference, Ending Age-Related Diseases 2018, in New York City a month ago. It was attended by a mix of advocates, scientists, entrepreneurs, and investors, all interested in seeing greater progress take place in the field of rejuvenation research. For those of us starting or running biotech companies to work on ways to treat aspects of aging, it was a good opportunity to network and make connections.
The presentations given at the conference were recorded, and are being tidied up and released for general viewing, as is the case for most of the conferences in our community. There was a greater emphasis on the business side of the house than usual at this event, and it is certainly the case that commercial biotechnology is becoming ever more important to efforts to treat aging as a medical condition. All of the fields of damage and damage repair described in the SENS rejuvenation research proposals are arguably at the stage where at least some part of the program might be commercially developed, given suitable levels of funding, or is being actively pursued by one or more companies.
Article originally posted at